The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) has reached its enrollment goal of 108,508 women, as announced today by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). The study ...
According to the World Health Organization, 1 in 12 women worldwide are diagnosed with breast cancer in their lifetime. Breast cancer remains one of the most prevalent, life-threatening diseases ...
Biomediq’s breast cancer risk analysis technology is centred around a mammographic texture risk biomarker model that recognises tissue heterogeneity, typically dubbed mammographic texture ...